Beijing, China – April 28, 2026 – PSI CRO, a Swiss-based global full-service contract research organization, today announced the opening of its second office in China, located in China World Tower B in Beijing’s Chaoyang District.
In 2019, PSI established its first China office in Shanghai, where the local team has steadily grown while supporting sponsors across the region. By adding a Beijing location, PSI brings its team closer to key drug regulatory authorities and leading research institutions.
China is playing an increasingly important role in global clinical development, creating a growing need for strong local operational and regulatory support. PSI’s presence in Beijing helps meet that need, combining local expertise with coordinated global teams to support clear decision-making and predictable, on-time delivery for sponsors.
For PSI, the Beijing office represents a targeted investment to support clients where it matters most – close to regulators, close to investigator sites, and close to strategic partners.
Lisa Lu, Country Manager, PSI China, explains:
“The opening of our Beijing office represents not just an expansion of PSI’s footprint, but a strategic commitment to strengthening our service capabilities in China. By establishing a presence in Beijing – a centralized hub for drug regulatory authorities and leading investigator sites – we are equipped with deep local knowledge and expertise to deliver high-quality, tailored solutions that address the unique challenges of this market. This expansion reinforces our belief that every patient counts.”
With its expanded presence in Beijing, alongside its established office in Shanghai, PSI continues to do what it has always done: combine global clinical expertise with local responsibility, ensuring sponsors receive reliable, high-quality support at every stage of development, making sure their clinical trials run on time.
PSI CRO is a global full-service contract research organization (CRO), committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. PSI’s key operational differentiator is on-time delivery of clinical trials. This metric remained above 90% in 2025.
The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, immunology, infectious diseases, neuroscience, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.
In 2025, PSI celebrated its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,200 people across 58 countries as of March 31st, 2026.
Global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300.
For more information, visit www.psi-cro.com.
